TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01847157

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham anesthesia
Description: 15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repeated passive movement
Description: Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated passive movement
Description: Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes.
Study: NCT02466074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT01847157

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
Study: NCT04081311

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparing interdental floss to water flosser around dental implants
Description: to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comparing interdental floss to water flosser around dental implants
Description: to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
Study: NCT01744054

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MR

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/CT
Study: NCT05058443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml [Prolia]
Description: denosumab subcutaneously every 6 months (Q6M)
Study: NCT00536874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
Study: NCT05058443

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo subcutaneously every 6 months (Q6M)
Study: NCT00848367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychodynamic Interpersonal Psychotherapy
Description: This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychodynamic Interpersonal Psychotherapy
Description: This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
Study: NCT04212104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watch a mukbang
Description: watch the dim sum mukbang

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: watch a non-food video
Description: watch the Big Bang Theory video
Study: NCT01269424

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MGMTP140K-encoding retroviral vector

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MGMTP140K-encoding retroviral vector
Study: NCT00536874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study: NCT04615429

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (solution identical to experimental treatment, without the MSC)
Study: NCT00959829

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Music and message
Description: Experimental group: music and message Control group: silence
Study: NCT01526928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily
Study: NCT01365715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriography and preoperative embolization
Description: Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriography
Description: Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
Study: NCT02411266

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ischemic conditioning group
Description: application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ischemic conditioning group
Description: application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
Study: NCT00836953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (Pediatric formulation)
Description: 0.25 mL, Intramuscular
Study: NCT02680366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen/ABMNC scaffold
Description: The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
Study: NCT00536874

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study: NCT02680366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter balloon
Description: The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
Study: NCT00642824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
Study: NCT03021707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLight® Ultraviolet Femtosecond (FS) Laser System
Description: Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
Study: NCT00536874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT00110071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT03021707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Assisted Lenticular Extraction
Description: Used for refractive error correction
Study: NCT03656146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Insecurity Screening Tablet
Description: The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Insecurity Screening Verbal
Description: The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
Study: NCT02150785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptokinase
Study: NCT00110071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 tositumomab
Description: Given IV (dosimetric dose) or via central line (therapeutic dose)
Study: NCT00997607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola vaccine
Description: 4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola vaccine
Description: 4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marburg vaccine
Description: 4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marburg vaccine
Description: 4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: 4 mg of saline injection delivered at Weeks 0, 4, and 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: 4 mg of saline injection delivered at Weeks 0, 4, and 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: 4 mg of saline injection delivered at Weeks 0, 4, and 8
Study: NCT02033824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM
Description: A piece of dHACM placed over any dural defect or dural closure during craniectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Craniectomy
Description: Removal of the skull flap followed by closure techniques per current SOC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniectomy
Description: Removal of the skull flap followed by closure techniques per current SOC.
Study: NCT02908945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSENSE monitor
Description: NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSENSE monitor
Description: NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
Study: NCT00110071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study: NCT02908945

Intervention type: DEVICE
Group type: OTHER
Intervention: NeuroSENSE monitor
Description: NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
Study: NCT04237909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection into at least one ovary
Description: The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
Study: NCT00894218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty
Description: Hip or knee arthroplasty
Study: NCT06762509

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Local injection of botulinum toxin type A was given at the time of enrollment
Study: NCT01661231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astron/Pulsar-18 stent
Description: Peripheral Vascular Intervention
Study: NCT00490126

Intervention type: OTHER
Intervention: Laparoscopic Surgery Data Collection
Description: Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
Study: NCT03257163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03638869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02818036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02491034

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Depression Education Intervention
Description: Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
Study: NCT00869050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle.
Study: NCT03849690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsules.
Study: NCT03251859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Description: Ticagrelor 90 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 mg
Description: Ticagrelor 90 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Ticagrelor 60 mg daily
Study: NCT05202665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICON DMG Resin Infiltration (micro-invasive approach)
Description: A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)
Description: Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
Study: NCT03297489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Undergo observation via intravital microscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium Injection
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies